Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

88 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Liver involvement in cystic fibrosis.
Colombo C, Crosignani A, Battezzati PM. Colombo C, et al. J Hepatol. 1999 Nov;31(5):946-54. doi: 10.1016/s0168-8278(99)80299-2. J Hepatol. 1999. PMID: 10580595 Review. No abstract available.
Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C, Crosignani A, Alicandro G, Zhang W, Biffi A, Motta V, Corti F, Setchell KDR. Colombo C, et al. Among authors: crosignani a. J Pediatr. 2016 Oct;177:59-65.e1. doi: 10.1016/j.jpeds.2016.05.008. Epub 2016 Jun 11. J Pediatr. 2016. PMID: 27297203
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Bruno S, et al. Among authors: crosignani a. J Hepatol. 2016 Jun;64(6):1217-23. doi: 10.1016/j.jhep.2016.01.034. Epub 2016 Apr 5. J Hepatol. 2016. PMID: 27059129
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, Almasio PL, Maisonneuve P. Bruno S, et al. Hepatology. 2010 Jun;51(6):2069-76. doi: 10.1002/hep.23528. Hepatology. 2010. PMID: 20196120

During a median follow-up of 11.4 years, 149/218 (68%) patients received antiviral treatment and 34 (22.8%) achieved SVR. None of the SVR patients developed EV compared with 22 (31.8%) of the 69 untreated subjects (P < 0.0001) and 45 (39.1%) of the 115 non-SVR patients

During a median follow-up of 11.4 years, 149/218 (68%) patients received antiviral treatment and 34 (22.8%) achieved SVR. None of the …
Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.
Fargion S, Bruno S, Borzio M, Battezzati PM, Bissoli F, Ceriani R, Orlandi A, Maraschi A, Chiesa A, Morini L, Fracanzani AL, Crosignani A, Fiorelli G, Podda M. Fargion S, et al. J Hepatol. 2003 Apr;38(4):499-505. doi: 10.1016/s0168-8278(02)00388-4. J Hepatol. 2003. PMID: 12663243
Persistently normal alanine aminotransferase and negative HCV RNA up to 72 weeks from treatment onset defined a sustained response. ...Compared with patients harboring non-1 genotypes, the odds ratio of being a non-responder was 1.68 (confidence interval (CI): 0.53- …
Persistently normal alanine aminotransferase and negative HCV RNA up to 72 weeks from treatment onset defined a sustained response. . …
Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis.
Alvaro D, Invernizzi P, Onori P, Franchitto A, De Santis A, Crosignani A, Sferra R, Ginanni-Corradini S, Mancino MG, Maggioni M, Attili AF, Podda M, Gaudio E. Alvaro D, et al. J Hepatol. 2004 Dec;41(6):905-12. doi: 10.1016/j.jhep.2004.08.022. J Hepatol. 2004. PMID: 15645536
In stage IV of PBC, cholangiocytes were negative for ER-alpha in association with a lower PCNA positivity and with maximal degree of ductopenia. ...
In stage IV of PBC, cholangiocytes were negative for ER-alpha in association with a lower PCNA positivity and with maximal degree of …
Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis.
Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, De Arias AE, Scalamogna M, Zuin M, Podda M. Invernizzi P, et al. J Hepatol. 2003 Apr;38(4):401-6. doi: 10.1016/s0168-8278(02)00440-3. J Hepatol. 2003. PMID: 12663229
RESULTS: HLA-DRB1*11 was associated with a markedly reduced risk of developing PBC (OR: 0.3; 95% CI: 0.2-0.5). No association was found with HLA-DRB1*08. ...CONCLUSIONS: Our data on a large series of Italian patients suggest that PBC may have a peculiar genet …
RESULTS: HLA-DRB1*11 was associated with a markedly reduced risk of developing PBC (OR: 0.3; 95% CI: 0.2-0.5). No association was fou …
Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome.
Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, Giunta A. Colombo C, et al. Hepatology. 2002 Dec;36(6):1374-82. doi: 10.1053/jhep.2002.37136. Hepatology. 2002. PMID: 12447862
Between 1980 and 1990, we enrolled 177 CF patients without LD in a systematic clinical, laboratory, ultrasonography screening program of at least a 10-year duration. ...Although LD does not condition a different clinical course of CF, in some patients it may …
Between 1980 and 1990, we enrolled 177 CF patients without LD in a systematic clinical, laboratory, ultrasonography screening program …
Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial.
Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, Merlini R, Batezzati PM, Crosignani A, Zuin M, et al. Bellentani S, et al. J Hepatol. 1993 Nov;19(3):459-64. doi: 10.1016/s0168-8278(05)80558-6. J Hepatol. 1993. PMID: 8151107 Clinical Trial.
Ursodeoxycholic acid (UDCA or ursodiol) administration has been associated with a reduction of serum liver enzymes in patients with chronic liver disease and with improvement of liver histology in patients with primary biliary cirrhosis. To establish the potential therapeu …
Ursodeoxycholic acid (UDCA or ursodiol) administration has been associated with a reduction of serum liver enzymes in patients with c …
Oral bile acids in cystic fibrosis-associated liver disease.
Colombo C, Crosignani A, Apostolo MG, Marzano MT, Bettinardi N, Giunta A. Colombo C, et al. J R Soc Med. 1994;87 Suppl 21(Suppl 21):20-4. J R Soc Med. 1994. PMID: 8201582 Free PMC article. Review. No abstract available.
88 results
Jump to page
Feedback